GlassScriptPhysician profile
Brian L Stucki
NPI 1588867477
$13,066.91
in general payments reported to CMS, 2019-2025
51 companies · $1,744 in 2025
The $1,744 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,368 · 2020: $1,128 · 2021: $1,814 · 2022: $1,548 · 2023: $2,254 · 2024: $2,211 · 2025: $1,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,123 · Education: $86.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,122.75 |
| Education | $86.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,741.42 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Emd Serono, INC. | $1,110.00 | 2019-2025 | Mavenclad |
| Biogen, INC. | $816.34 | 2019-2025 | Tysabri, Vumerity, Plegridy |
| Acadia Pharmaceuticals INC | $699.22 | 2019-2022 | |
| Ucb, INC. | $666.20 | 2019-2025 | Briviact, Zilbrysq, Rystiggo |
| Sk Life Science, INC. | $563.00 | 2021-2025 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $513.26 | 2019-2025 | Austedo Xr |
| Celgene Corporation | $487.02 | 2022-2025 | Zeposia |
| Allergan, INC. | $477.00 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $418.01 | 2019-2025 | |
| Genzyme Corporation | $405.42 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $338.42 | 2019-2021 | |
| Livanova USA, INC. | $330.41 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Amgen INC. | $301.01 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $284.61 | 2019-2025 | Ultomiris |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Stucki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.